A Biodegradable Stent Based on Poly(L-Lactide) and Poly(4-Hydroxybutyrate) for Peripheral Vascular Application: Preliminary Experience in the Pig

Abstract

Purpose:

To assess the technical feasibility and biocompatibility of a novel stent based on poly(L-lactide) (PLLA) and poly(4-hydroxybutyrate) (P4HB) for peripheral vascular applications.

Methods:

A polytetrafluoroethylene aortobi-iliac graft was implanted in 5 pigs through a midline abdominal incision. After transverse graft limb incision, 5 PLLA/P4HB stents and 5 metal stents (316L stainless steel) were randomly deployed at both iliac anastomotic sites with 6-mm balloon catheters. Angiography was performed to determine patency prior to sacrifice at 6 weeks. Stented segments were surgically explanted and processed for quantitative histomorphometry. Vascular injury and inflammation scores were assigned to the stented iliac segments.

Results:

No animals were lost during follow-up. All PLLA/P4HB stents were deployed within 2 minutes by balloon inflation to 8 bars without rupture of the stent struts or anastomotic suture. All stents were patent on postprocedural angiography. Histological analysis showed no signs of excessive recoiling or collapse. PLLA/P4HB stents demonstrated decreased residual lumen area and increased neointimal area after 6 weeks (12.27±0.62 and 8.40±1.03 mm², respectively) compared to 316L stents (13.54±0.84 and 6.90±1.11 mm², respectively) as the result of differences in stent areas (PLLA/P4HB: 4.31±0.15 mm²; 316L: 2.73±0.29 mm²). Vascular injury scores showed only mild vascular trauma for all stents (PLLA/P4HB: 0.41±0.59; 316L: 0.32±0.47). Inflammatory reaction was slightly higher around PLLA/P4HB stent struts (1.39±0.52) compared to 316L (1.09±0.50).

Conclusion: Rapid balloon expansion of PLLA/P4HB stents is feasible without risk of strut rupture. PLLA/P4HB stents provide adequate mechanical stability after iliac anastomotic stenting in pigs. Smaller residual luminal areas in the PLLA/P4HB stents might have been caused by tissue ingrowth into the larger strut interspaces due to higher strut thickness (stent area) in this group. This limitation needs to be addressed in future work on the stent design.

Keywords

experimental study porcine model biodegradable stent balloon-expandable stent anastomotic stent poly(L-lactide)poly(4-hydroxybutyrate)

Get full access to this article

View all access options for this article.

References

Kornowski

Hong

Tio

. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998; 31: 224–230.

Sullivan

Ainsworth

Langan

. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. J Vasc Surg. 2002; 36: 143–149.

Tamai

Igaki

Kyo

. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102: 399–404.

Ormiston

Webster

Armstrong

. First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007; 69: 128–131.

Grabow

Schlun

Sternberg

. Mechanical properties of laser cut poly-L-lactide micro-specimens: Implications for stent design, manufacture, and sterilization. J Biomech Eng. 2005; 127: 25–31.

Grabow

Bunger

Sternberg

. Mechanical properties of a biodegradable balloon-expandable stent from poly(l-lactide) for peripheral vascular applications. J Med Devices. 2007; 1: 84–88.

Dyet

Watts

Ettles

. Mechanical properties of metallic stents: How do these properties influence the choice of stent for specific lesions? Cardiovasc Intervent Radiol. 2000; 23: 47–54.

Bünger

Grabow

Sternberg

. Iliac anastomotic stenting with a biodegradable poly-L-lactide stent: A preliminary study after 1 and 6 weeks. J Endovasc Ther. 2006; 13: 539–548.

Bünger

Grabow

Kröger

. Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-L-lactide stent: A preliminary study after 6 weeks. J Endovasc Ther. 2006; 13: 630–639.

10.

Martin

Williams

. Medical applications of poly-4-hydroxybutyrate: A strong flexible absorbable material. Biochem Eng J. 2003; 16: 97–105.

11.

Grabow

Bünger

Schultze

. A biodegradable slotted tube stent based on poly(l-lactide) and poly(4-hydroxybutyrate) for rapid balloon expansion. Ann Biomed Eng. 2007; in press.

12.

Schwartz

Huber

Murphy

. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol. 1992; 19: 267–274.

13.

Waksman

. Biodegradable stents: They do their job and disappear. J Invasive Cardiol. 2006; 18: 70–74.

14.

Erne

Schier

Resink

. The road to bioabsorbable stents: Reaching clinical reality? Cardiovasc Intervent Radiol. 2006; 29: 11–16.

15.

Uurto

Juuti

Parkkinen

. Biodegradable self-expanding poly-L/D-lactic acid vascular stent: A pilot study in canine and porcine iliac arteries. J Endovasc Ther. 2004; 11: 712–718.

16.

Aggrawal

Haas

Leopold

. Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. Biomaterials. 1992; 13: 176–182.

17.

Hietala

Salminen

Stahls

. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J Vasc Res. 2001; 38: 361–369.

18.

Chao

Landau

. Expandable bioresorbable endovascular stent. I. Fabrication and properties. Ann Biomed Eng. 2003; 31: 667–677.

19.

Schellhammer

Berlis

Bloss

. Poly-lactic-acid coating for endovascular stents. Preliminary results in canine experimental arteriovenous fistulae. Invest Radiol. 1997; 32: 180–186.

20.

Unverdorben

Spielberger

Schywalsky

. A polyhydroxybutyrate biodegradable stent: Preliminary experience in the rabbit. Cardiovasc Intervent Radiol. 2002; 25: 127–132.

21.

Vogt

Stein

Rettemeier

. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J. 2004; 25: 1330–1340.

22.

Uurto

Mikkonen

Parkkinen

. Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: An experimental pilot study. J Endovasc Ther. 2005; 12: 371–379.

23.

Yamawaki

Shimokawa

Kozai

. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998; 32: 780–786.